Kyorin pact another arrow in Daiichi Sankyo's South American quiver
This article was originally published in Scrip
Executive Summary
In another move to build up its business in major emerging markets, Daiichi Sankyo has acquired exclusive development and commercialisation rights in Brazil to Kyorin Pharmaceutical's overactive bladder therapy imidafenacin.